Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is an independent cardiovascular risk factor. We investigated the plasma levels of Lp-PLA 2 activity and mass as a function of plasma lipid levels, LDL subclass profile and oxidative stress in patients with β-thalassemia. Thirty-five patients with β-thalassemia major (β-TM) and 25 patients with β-thalassemia intermedia (β-TI) participated in the study. Lp-PLA 2 activity and mass were measured in total plasma, in apo B-depleted plasma (HDL-Lp-PLA 2 ) and in LDL subclasses. Lp-PLA 2 activity produced and secreted from peripheral blood monocytes in culture was also determined. Patients with β-thalassemia are characterized by a predominance of small-dense LDL particles, increased oxidative stress as well as very high plasma levels of Lp-PLA 2 mass and activity, despite the low LDL-cholesterol levels.
9
= 1.029 -1.039 g/ml), LDL-4 (d = 1.039-1.050 g/mL), and LDL-5 (d = 1.050-1.063 g/ml) (22). All subfractions were dialyzed extensively at 4°C in 10 mmol/L phosphatebuffered saline, pH 7.4 (PBS) containing 2 mmol/L EDTA, filter-sterilized, and maintained at 4°C under nitrogen until analysis. Under these storage conditions, no oxidation was observed in each LDL subfraction, as it was revealed by agarose gel electrophoresis and the determination of the TBARS values (0.9 ± 0.4 malondialdehyde equivalents per mg of protein for all lipoprotein preparations).
Preparation of erythrocyte lysates
Erythrocyte lysates were prepared as we have described previously (19) . In brief, venous blood samples were collected using acid citrate as anticoagulant and centrifuged at 1500xg for 20 min. The supernatant plasma along with the buffy coat was removed by aspiration. The remaining erythrocyte pellet was washed three times with a 4.2 mM Hepes buffer solution pH 7.4. A small portion of this suspension was used for erythrocyte count. The remaining suspension was centrifuged as above and the sedimented erythrocytes were lysed by mixing with 5 volumes of a 7 mM sodium phoshate buffer solution, pH 7.4 for 20 min at -4 o C (19) . The erythrocyte lysate was stored at -80 o C until analysis.
Measurement of Lp-PLA 2 activity and mass
Lp-PLA 2 activity in total plasma, in apo B-depleted plasma, after the sedimentation of all apo B-containing lipoproteins with dextran sulfate-magnesium chloride (HDL-Lp-PLA 2 activity) and in LDL subclasses, was determined by the trichloroacetic acid by guest, on October 22, 2017 www.jlr.org Downloaded from citrate dextrose as an anticoagulant (Vacutainer, Becton Dickinson) and centrifuged at 150 g for 10 min to obtain platelet-rich plasma. Platelet-rich plasma was then mixed with 0.1% EDTA/saline, at a ratio of 3:2 (v/v) and then centrifuged at 1,500 g for 20 min to obtain the plasma-containing microparticles. Flow cytometry was then performed, to verify the presence of platelet microparticles by using annexin-V-PE, which recognizes the population of all microparticles that express anionic phospholipids and anti-CD41a-FITC, which is specific for platelet microparticles (PMPs) (25). The Lp-PLA 2 activity associated with PMPs in plasma was then measured by a captured ELISA method previously described by our group using ELISA plates were coated with the monoclonal antibody anti-CD61 (it specifically recognizes the β 3 integrin of the platelet integrin α ΙΙb β 3 located on PMPs) or the isotype-matched mouse monoclonal IgG (25).
Isolation and culture of peripheral blood monocytes
Peripheral blood from patients with β-thalassemia as well as from controls was drawn into EDTA-containing tubes. Blood was centrifuged and monocytes were isolated from the buffy coats as we previously described (23). Cells from each donor were cultured and grown in duplicate in 24-well plastic tissue culture dishes (1 x 10 6 cells/well) with RPMI medium, containing L-glutamine, 40 µg/mL gentamycin and 1% Nutridoma (Boehringer Mannheim GmbH, Germany) (23). After 48h of culture, the cell supernatants were recovered and the cell layers were washed twice with PBS and then detached and lysed by the addition of 0.2 ml of a lysis solution containing 1% EDTA and 0.1% Triton X-100. Both supernatants and cell lysates were centrifuged (500 x g for 10 min at 4ºC), stored at 4ºC and analyzed for Lp-PLA 2 activity and lactate dehydrogenase activity (kit from Boehringer Mannheim GmbH, Germany) within 24h from the collection (23, 26). Cell lysates were further analyzed for their protein content, determined with the Lowry method (26). Viability under all culture conditions was determined by trypan blue dye exclusion and the absence of lactate dehydrogenase release; viability was > 95%.
Measurement of PON1 activities
PON1 activities in serum were measured using paraoxon as a substrate (paraoxonase activity), as well as using phenyl acetate as a substrate (arylesterase ativity). Both PON1 activities were determined in the presence of 2 mM Ca 2+ in 100 mM Tris-HCl buffer (pH 8.0) for paraoxon and in 20 mM Tris-HCl buffer (pH 8.0) for phenyl acetate (26).
Determination of 8-isoprostanes
For estimation of oxidative stress in all subjects participated in the present study, the plasma and urine levels of 8-isoprostanes (8-epiPGF2a), were determined. Measurement of 8-epiPGF2a levels in plasma samples (expressed as pg/ml) was carried out by means of a competitive enzyme immunoassay (commercial 8-isoprostane EIA kit, Cayman Chemicals, Ann Arbor, MI, USA), following the manufacturer instructions as we previously described (27). The 8-epiPGF2a levels in urine were also determined by the same technique and were expressed as ng/mg creatinine.
Statistical analysis
Data are presented as the mean (SD) except for nongaussian-distributed variables, which are presented as the median (range). Statistical analyses were performed using ANOVA followed by least significant difference (LSD) test for comparisons between individual groups. The nonparametric Mann-Whitney U test and the Kruskal-Wallis test were applied to discriminate differences in nongaussian-distributed variables.
Correlations between Lp-PLA 2 and other parameters determined in the present study were estimated using linear regression analysis and Spearman's rank correlation coefficients (for nongaussian-distributed variables), while Yates's corrected chi-square test was used for differences in proportions. A P value of <0.05 was considered to be significant.
Results

Characteristics of the study population
The clinical and biochemical characteristics of the study population are shown in Table 1 . Both thalassemic patients groups exhibited elevated serum ferritin levels compared with controls. Liver biopsy was performed in 12 patients. Histologically, hepatitis and cirrhosis were found in four and one of these patients, respectively.
Moreover, severe hepatic siderosis could be shown in 2 out of the 12 patients. Nineteen (55%) of the patients were on optimal desferrioxamine therapy, whereas history of splenectomy, endocrinopathy and active or healed hepatitis was evident in a significant minority of them. Both patient groups demonstrated significantly lower serum total-, LDL-and HDL-cholesterol levels and increased concentrations of both serum triglycerides and liver transaminases compared with controls, whereas no difference in the above parameters was observed between β-TI and β-TM. No difference in the serum Lp(a) and glucose levels was also observed among the studied groups. The atherogenic ratio LDL-cholesterol to HDL-cholesterol was significantly lower in both patient groups compared with controls ( Table 1 ). The proinflammatory cytokines IL-6 and TNF-α were significantly higher in both patient groups compared with controls, the β-TM patients exhibiting higher levels of both parameters compared with β-TI ( Table 1) . Finally on ultrasonography, the mean IMT values in β-TM patients were 0.50±0.14 mm, in accordance to our recently reported values on these patients (16) .
Apolipoprotein B-containing lipoprotein subclasses
Both β-TI and β-TM patient groups had higher plasma levels of VLDL-cholesterol and lower levels of IDL-cholesterol and buoyant LDL-cholesterol compared with control group (Table 2) . Furthermore, β-TI and β-TM patients had significantly higher levels of sdLDL-cholesterol and a higher proportion of sdLDL, whereas the mean LDL size was lower compared with the subjects of control group. Finally, no difference was observed between the two patient groups in the above parameters (Table 2) .
Plasma Lp-PLA 2 activity and mass
Total plasma Lp-PLA 2 activity as well as the enzyme mass were significantly higher in both patient groups compared with controls, the β-TM patients having significantly higher enzyme activity and mass compared with β-TI patients (Table 1) . Lp-PLA 2 activity and mass in thalassemic patients were positively correlated with 8-epiPGF2a levels in serum (r=0.245, p<0.03 and r=0.288, p<0.03, respectively) and in urine (r=0.310, p<0.02 and r=0.328, p<0.02, respectively). A positive correlation was also observed between Lp-PLA 2 activity and mass with serum ferritin levels (Fig. 1A,B) whereas no correlation was found between Lp-PLA 2 activity or mass and LDLcholesterol ( Fig. 1C,D) , total cholesterol, or Lp(a) levels in both patient groups. Finally a significant correlation between plasma Lp-PLA 2 activity and mass with IMT values in β-TM patients was observed (r= 0.440, p<0.01 and r= 0.463, p<0.01, respectively).
Importantly, the enzyme specific activity in total plasma (calculated as the activity to mass ratio) in both patient groups was significantly lower (p<0.05) compared with controls (in nmol/ng/min, 0.17 0.03 for controls, versus 0.13 0.03 for β-TI and 0.13 0.02 for β-TM patients). Similarly, the HDL-Lp-PLA 2 activity and mass were significantly higher compared with controls, the β-TM patients having significantly higher enzyme activity and mass compared with β-TI patients (Table 1) , whereas in both patient groups, the enzyme specific activity was significantly lower (p<0.05) compared with controls (0.045±0.01 for controls, versus 0.039±0.02 for β-TI and 0.038±0.01 for β-TM patients). Finally, the ratio of HDL-Lp-PLA 2 mass to total plasma Lp-PLA 2 mass was significantly higher (p<0.001) in both patient groups compared with controls (0.11±0.01 for controls, versus 0.14±0.02 for β-TI and 0.15±0.02 for β-TM patients).
Similarly, the ratio of HDL-Lp-PLA 2 activity to total plasma Lp-PLA 2 activity was significantly higher (p<0.001) in both patient groups compared with controls (0.26±0.03
for controls, versus 0.52±0.04 for β-TI and 0.65±0.04 for β-TM patients).
Lp-PLA 2 activity and mass in apolipoprotein B-containing lipoprotein subfractions
The higher Lp-PLA 2 activity and mass found in plasma of β-TM and β-TI patients despite their lower plasma levels of LDL-cholesterol, led us to determine the above enzyme parameters in apolipoprotein B (apoB)-containing lipoprotein subfractions prepared by an isopycnic density gradient ultracentrifugation method. The Lp-PLA 2 activity and mass were preferentially associated with the small dense LDL-5 subfraction in all studied groups (Fig. 2) . Importantly, β-TM and β-TI patients exhibited higher enzyme activity and mass in all lipoprotein subfractions compared with controls, the β-TM patients having significantly higher enzyme activity and mass compared with β-TI patients ( Fig. 2) .
The PAF-acetylhydrolase of erythrocytes does not contribute to the pool of plasma
Lp-PLA 2 of patients with β-thalassemia
The elevated Lp-PLA 2 activity and mass in plasma of patients with β-thalassaemia prompted us to study the source(s) from which this high amount of enzyme derives. We initially searched whether hemolysis, a phenomenon that occurs in these patients could contribute to the increased Lp-PLA 2 in plasma. Indeed erythrocytes contain a PAFacetylhydrolase type that exhibits similar substrate specificity but it is structurally different to that of Lp-PLA 2 (3). The enzyme activity determined in erythrocyte lysates prepared from blood of five subjects from each group was similar among the study groups (in nmol/10 9 cells/min, 73±8 for controls, 70±10 for β-TI patients and 75±11 for β-TM patients). As expected, the enzyme activity in erythrocyte lysates was sensitive to sulfhydryl reagents (28) since it was significantly reduced by 75±5% in all groups after treatment with 1mM 5,5'-dithiobis (2-nitrobenzoic acid), (DTNB) for 30 min at 37°C.
Furthermore, as it was previously reported (28), the enzyme activity in erythrocyte lysates was susceptible to proteolysis since it was significantly reduced by 90±10% in all groups after treatment with 0.25 mg /ml Trypsin for 1h at 37°C. By contrast, the plasma Lp-PLA 2 activity in all studied groups was resistant to the above treatments.
Additionally, we were not able to detect Lp-PLA 2 mass in erythrocyte lysates, indicating that the PLAC test does not detect the PAF-acetylhydrolase type that exists in erythrocytes. Overall, the above results suggest that the increase in Lp-PLA 2 mass and activity in plasma of β-TM and β-TI patients is not due to the existence in plasma of the enzyme type derived from erythrocytes.
Lp-PLA 2 activity associated with platelet microparticles in plasma of patients with β-thalassemia
As we have previously shown, another source of the Lp-PLA 2 in plasma could be platelets, which secrete this enzyme associated with platelet microplates (PMPs) (25). By using an ELISA method previously described by our group, we determined the PMPs associated enzyme in plasma of β-TM and β-TI patients as well as of controls.
Representative flow cytometric profile of PMPs in plasma of β-TM patients is illustrated in Fig. 3A . Similar profiles were obtained in plasma of β-TI patients and controls. As it is shown in Fig. 3B , The PMPs-associated enzyme activity was similar among all studied groups suggesting that the increase in plasma Lp-PLA 2 observed in β-TM and β-TI patients is not due to an increase in the enzyme secretion from platelets of these patients.
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It has been shown that adherent monocytes produce and secrete Lp-PLA 2 during differentiation into macrophages, and these cells represent the major source of the plasma Lp-PLA 2 activity (5, 6). To investigate whether the increase in plasma-and HDL-Lp-PLA 2 activity of patients with β-thalassemia was due to an increase in enzyme secretion from monocytes in culture, we studied the spontaneous enzyme secretion form monocytes of both groups as well as from controls. As it is shown in Fig. 4A , there was an increase in total (secreted plus cell-associated) Lp-PLA 2 activity in both patient groups compared with controls at 48 hours of culture (p<0.01) and this increase reflected mainly the secreted enzyme activity (Fig. 4B ). Importantly the total and secreted enzyme activity in β-ΤΜ patients was significantly higher compared to those observed in β-ΤI patients (p<0.03) (Fig. 4A,B) . It should be noted that in preliminary experiments we attempted to determine the enzyme mass in the supernatants and in cell lysates using the PLAC test.
However, we were not able to detect any mass in our samples possibly due to the fact that the Lp-PLA 2 mass was lower than the detection limit of this kit which is 1.2 ng/ml (24).
Paraoxonase-1 activities and 8-epiPGF2a levels
The serum paraoxonase-1 (PON1) activities towards paraoxon as well as towards phenylacetate were significantly lower in both patient groups compared with controls whereas no difference was observed between patient groups (Table 3) . Furthermore, both patient groups had significantly higher levels of serum and urine 8-isoprostane (8-epiPGF2a), an established marker of lipid peroxidation, compared with controls, the β-TM patients having significantly higher levels of 8-epiPGF2a compared with β-TI patients (Table 3) . 
Discussion
The present study shows for the first time that patients with β-thalassemia exhibit very high plasma levels of Lp-PLA 2 mass and activity, these parameters being significantly higher in β-TM compared with β-TI patients. Major determinants of Lp-PLA 2 levels in plasma are the LDL levels as well as the rate of LDL clearance from the circulation (18, 26) . In the present study both patient groups exhibit low LDL-cholesterol levels, thus this is the first report for a population with low LDL-cholesterol levels that exhibits so high plasma levels of Lp-PLA 2 . Notably, the LDL-cholesterol or the total cholesterol levels in thalassemic patients are not correlated with enzyme mass or activity, in contrast to that expected based on the results from most published to date studies, including those from our group (18, 26). As we have previously shown, the majority of the LDL-associated Lp-PLA 2 is bound to atherogenic sdLDL particles in both normolipidemic and dyslipidemic population (18, 22, 26, 29) . Our results revealed that both patient groups are characterized by a predominance of sdLDL particles, a finding that is consistent with their elevated fasting triglyceride levels (30). Furthermore, sdLDL particles (LDL-5) carry the majority of LDL-associated Lp-PLA 2 . Thus the predominance of sdLDL particles enriched in Lp-PLA 2 in plasma of β-thalassemic patients could contribute to the high enzyme mass and activity observed in these patients despite the low LDLcholesterol levels (Fig. 5) .
The increased hemolysis occurring in β-thalassemia could also contribute to the elevated plasma enzyme observed in these patients. However this hypothesis is unlikely since neither the method used to determine the enzyme mass in plasma detects the erythrocyte PAF-acetylhydrolase in the lysates of these cells, despite the relatively high enzyme activity, nor the plasma enzyme in our patients exhibits any sensitivity to the treatments with sulfhydryl reagents or proteases in contrast to the erythrocyte enzyme. A source of Lp-PLA 2 in plasma is platelets that secrete this enzyme associated with PMPs (25). Platelets in β-thalassemia undergo a state of oxidative stress, leading to their activation (31). Thus platelets could contribute to the elevation in plasma Lp-PLA 2 of our patients since they exhibit increased oxidative stress as it is indicated by the elevation of serum and urine 8-epiPGF2a, an established marker of lipid peroxidation, which is correlated with Lp-PLA 2 activity and mass. However the above hypothesis is unlikely since the Lp-PLA 2 activity associated with PMPs in plasma of our patients is not different compared with controls.
In contrast to platelets, monocytes/macrophages, the major cellular source of plasma Lp-PLA 2 may significantly contribute to the elevation in plasma enzyme observed in β-thalassemia since an increased Lp-PLA 2 production and secretion from monocytes in culture is observed in both patient groups (Fig. 5) . This phenomenon could be at least partially due to the increased oxidative stress that has been attributed to the high plasma iron turnover observed in patients with β-thalassemia (32, 33). Indeed, the plasma ferritin levels, a measure of body and macrophage iron content and a potent pro-oxidant, are a potential modulator of Lp-PLA 2 activity in plasma (34). Consistent to the above suggestion are the results of the present study showing that the increased plasma ferritin levels in β-thalassemic patients are strongly correlated with Lp-PLA 2 activity and mass.
Patients with β-thalassemia exhibit increased inflammation (32) that may also contribute to the elevation in plasma Lp-PLA 2 . In this regard it has been reported that the only proinflammatory mediator that stimulates the expression and secretion of Lp-PLA 2 by monocyte/macrophages is PAF (35). As we (36) and others (37) have shown, PAF and structurally related oxidized phospholipids are formed during LDL oxidation; these molecules being elevated in patients with increased oxidative stress (38). Increased plasma levels of various lipid peroxidation products and marked LDL oxidative modification have been reported in thalassemic patients (33). Thus a contributory role in the enhanced secretion of Lp-PLA 2 from monocytes/macrophages observed in our patients may be played by proinflammatory phospholipids such as PAF and structurally related oxidized phospholipids formed under conditions of increased oxidative stress, a hypothesis that needs further investigation (Fig 5) . Some of the β-thalassemic patients exhibit liver disease or hypothyroidism that might have influenced the plasma Lp-PLA 2 levels. However when we excluded these patients from the statistical analysis, the differences in Lp-PLA 2 levels among studied groups were not altered (data not shown).
Finally, differences in genetic expression of Lp-PLA 2 between patients with β-thalassemia and controls that may lead to increased Lp-PLA 2 expression and secretion from patient monocytes may not be excluded (Fig 5) .
An important observation of our study is that the specific activity of Lp-PLA 2, ie the activity expressed per enzyme mass, is lower in our patients compared with controls.
Since the enzyme is susceptible to oxidative inactivation (reviewed in Ref. 1), the decreased Lp-PLA 2 specific activity could be attributed to the increased oxidative stress observed in these patients. Hence, we may suggest that the enhanced production and secretion of new active enzyme from monocytes/macrophages could counteract the oxidative stress-induced partial enzyme inhibition, thereby resulting in an overall increase in plasma Lp-PLA 2 activity.
Similarly to the total plasma Lp-PLA 2 , the HDL-Lp-PLA 2 is also elevated in both patient groups, despite the low HDL-cholesterol levels and it could also be primarily attributed to the enhanced enzyme secretion from monocytes/macrophages. Furthermore, the specific HDL-Lp-PLA 2 activity is decreased possibly due to its partial inactivation from the increased oxidative stress observed in these patients. The increased oxidative stress could also be responsible for the reduced PON1 activities observed in our patients.
Indeed like Lp-PLA 2 , PON1 is also susceptible to oxidative inactivation (39).
The findings of the present study may be clinically important since patients with β-thalassemia exhibit endothelial dysfunction, premature carotid atherosclerosis (16) and high incidence of stroke despite their very uncommon rates of coronary artery disease (13, 16). Lp-PLA 2 is independently associated with endothelial dysfunction (40) and is highly expressed in carotid artery plaques (41). The significant correlation of plasma Lp-PLA 2 concentrations with carotid artery IMT values found in our β-TM patients, implies that this enzyme may be implicated in premature carotid atherosclerosis observed in β-thalassemia. Clinical studies have demonstrated that increased plasma Lp-PLA 2 levels are associated with high incidence of stroke (42). Our β-thalassemic patients exhibit high plasma Lp-PLA 2 levels but low LDL-cholesterol levels and low atherogenic LDLcholesterol / HDL-cholesterol ratio. They are also presented with high levels of the antiatherogenic HDL-Lp-PLA 2 and the ratio of HDL-Lp-PLA 2 to total plasma enzyme, which could be a potential antiatherogenic marker in patients with dyslipidemia (18) .
Considering that dyslipidemias have long been associated with coronary artery disease, but not with cerebrovascular disease (43), and that carotid artery disease could be a possible cause of stroke in cardiac disease-free patients with β-thalassemia (44), we may suggest that the high plasma Lp-PLA 2 levels in the presence of a relatively antiatherogenic cholesterol profile may contribute to premature carotid atherosclerosis and high incidence of stroke observed in patients with β-thalassemia (13, 16) but not to coronary artery disease (Fig. 5) .
In conclusion, patients with β-thalassemia exhibit high plasma Lp-PLA 2 levels, which could be primarily attributed to increased enzyme production and secretion from monocytes/macrophages as well as to the predominance of sdLDL particles in plasma. 
